2026-04-29T01:50:35Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/173282024-09-21T21:45:08Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927

00925njm 22002777a 4500 dc Pinto-Medel, María Jesús author Oliver-Martos, Begoña author Urbaneja-Romero, Patricia author Hurtado-Guerrero, Isaac author Ortega-Pinazo, Jesús author Serrano-Castro, Pedro author Fernández, Óscar author Leyva, Laura author 2017-08-18 The alteration of DNA methylation patterns are a key component of disease onset and/or progression. Our objective was to evaluate the differences in Long Interspersed Nuclear Element-1 (LINE-1) methylation levels, as a surrogate marker of global DNA methylation, between multiple sclerosis (MS) patients and healthy controls. In addition, we assessed the association of LINE-1 methylation with clinical disease activity in patients treated with IFNbeta (IFNβ). We found that individuals with high levels of LINE-1 methylation showed 6-fold increased risk of suffering MS. Additionally, treated MS patients who bear high LINE-1 methylation levels had an 11-fold increased risk of clinical activity. Moreover, a negative correlation between treatment duration and percentage of LINE-1 methylation, that was statistically significant exclusively in the group of patients without clinical activity, was observed. Our data suggest that in MS patients, a slight global DNA hypermethylation occurs that may be related to the pathophysiology of the disease. In addition, global DNA methylation levels could play a role as a biomarker for the differential clinical response to IFNβ. http://hdl.handle.net/10668/11520 http://hdl.handle.net/20.500.12105/17328 28821874 10.1038/s41598-017-09301-2 2045-2322 Scientific reports Global methylation correlates with clinical status in multiple sclerosis patients in the first year of IFNbeta treatment.